Automate Your Wheel Strategy on SNY
With Tiblio's Option Bot, you can configure your own wheel strategy including SNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNY
- Rev/Share 17.2983
- Book/Share 30.1835
- PB 1.464
- Debt/Equity 0.1847
- CurrentRatio 1.0603
- ROIC 0.0612
- MktCap 108369252153.1446
- FreeCF/Share 0.8591
- PFCF 51.777
- PE 11.77
- Debt/Assets 0.1043
- DivYield 0.0434
- ROE 0.1236
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SNY | Morgan Stanley | Equal Weight | Overweight | -- | $58 | Sept. 8, 2025 |
| Upgrade | SNY | Deutsche Bank | Hold | Buy | -- | -- | Sept. 2, 2025 |
| Upgrade | SNY | JP Morgan | Neutral | Overweight | -- | -- | Aug. 8, 2025 |
| Initiation | SNY | Exane BNP Paribas | -- | Outperform | -- | $65 | April 15, 2025 |
| Initiation | SNY | Goldman | -- | Neutral | -- | $65 | March 21, 2025 |
| Upgrade | SNY | Deutsche Bank | Sell | Hold | -- | -- | Jan. 30, 2025 |
News
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025 . Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in Opella to CD&R.
Read More
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
Read More
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d'Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
Read More
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasive E.
Read More
About Sanofi (SNY)
- IPO Date 2002-07-01
- Website https://www.sanofi.com
- Industry Drug Manufacturers - General
- CEO Paul Hudson
- Employees 82878